For further information on abstract deadlines, please contact email@example.com.
Churchill College is an ideal venue for exhibitors. All refreshments, the exhibition and posters will be situated in a single area, ensuring excellent access to delegates throughout the meeting.
The exhibition will run alongside the conference during refreshment breaks and poster sessions. Those who wish to exhibit are encouraged to book early to avoid disappointment. Exhibition stands will be available to book via the registration page when registration opens, and the rate will include two stand staff and daytime refreshments.
For further details, please contact firstname.lastname@example.org
The discovery of sebetralstat, an oral, small molecule oral plasma kallikrein inhibitor to treat attacks of hereditary angioedema
Rebecca Davie, KalVista
Discovery of reversible highly potent and selective MAGL inhibitors
Uwe Grether, Roche
Discovery and first-time disclosure of NT-0796, a clinical phase NLRP3 inflammasome inhibitor for inflammation
David Harrison, NodThera
LMW inhibitors of IL-1β, from fragment hits to cellular PoC
Konstanze Hurth, Novartis Institutes for BioMedica
Discovery of LAS202051, a potent Acetyl-CoA Carboxylase (ACC) inhibitor for the topical treatment of acne
Jordi Bach Taña, Almirall
Discovery of a novel class of brain penetrant inhibitors of KRAS G12C
Jason Kettle, AstraZeneca
Fadaltran, a Selective Antagonist for the Peripheral AR alpha 2c Receptors: A New Option for the Treatment of Diabetic Foot Ulcers?
Carsten Schmeck, Bayer
Fragment-based drug discovery approaches to the development of protein-protein interaction inhibitors
Dr John Skidmore, The ALBORADA Drug Discovery Institute, University of Cambridge
Plasmepsin X inhibitors with in vivo antimalarial activity
Teresa de Haro Garcia, UCB
Discovery of VX-147 as a Targeted Therapy for APOL1‑mediated Kidney Disease’
Les Dakin, Vertex
Lessons Learnt building the GSK pan-BET bromodomain portfolio
Phil Humphreys, GSK
Gamma Secretase Modulator for the treatment of Alzheimer's Disease
Rosa Maria Rodriguez Sarmiento, Hoffman La Roche
SAGE-718, a compound in phase II for a variety of CNS indications. (NMDAR PAM)
Tel: +44 (0)20 7598 1561
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations